Published in Biotech Business Week, December 20th, 2004
A total of six dosing-cohorts is planned under the study, with five ALS patients per dosing-cohort (four receiving AEOL 10150, one receiving placebo). Each single dose per dosing-cohort will be increased as the trial progresses. The phase I clinical trial is expected to be conducted at six clinical sites within the United States and is intended to evaluate the safety, tolerability and pharmacokinetics of AEOL 10150.
The initial dosing-cohort of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.